Cialis for the Treatment of Benign Prostatic Hyperplasia

Adverse effects
What Are the Key Risks and Uncertainties?
Companies anticipate providing over-the-counter (OTC) product to treat erectile dysfunction after expiration of certain patents
Mechanism of action
More about Cialis (tadalafil)
Key Takeaways: Cialis vs Tadalafil

Wishing Grünenthal great success in this new chapter!

Adverse effects

These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's and Lilly's management believe that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of the companies, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. In particular, there are no guarantees that regulatory authorities will approve Cialis for nonprescription use. Risks and uncertainties also include, among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Companies' ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2013, and in the public filings with the SEC made by Lilly, including those listed under "risk Factors" in Lilly's annual report on Form 10-K for the year ended December 31, 2013. All the best, Nice to see this kind proyects in Latin America 👏 PARIS and INDIANAPOLIS, May 28, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Eli Lilly and Company (NYSE: LLY) today announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). Cialis is currently available by prescription only worldwide for the treatment of men with erectile dysfunction (ED). Under the terms of the agreement, Sanofi acquires the exclusive rights to apply for approval of Cialis OTC in the United States, Europe, Canada and Australia. Sanofi also holds exclusive rights to market Cialis OTC following Sanofi's receipt of all necessary regulatory approvals. If approved, Sanofi anticipates providing Cialis OTC after expiration of certain patents. Terms of the licensing agreement were not disclosed. "This agreement provides us with an opportunity to work with Lilly, a leader in men's health, to transform how this important medicine is offered to millions of men throughout the world," said Vincent Warnery, senior vice president, Global Consumer Healthcare Division, Sanofi. "The opportunity to forge an industry-leading partnership that adds to Sanofi Consumer Healthcare's leading portfolio and successful track record of over-the-counter switches reinforces consumer health care as a major growth platform for Sanofi." "Millions of men worldwide trust Cialis to treat ED.

Cialis Lilly’s tadalafil is distinct for its longer half-life compared to sildenafil (Viagra).
Patients report improvements in sexual performance and confidence.
It also helps relieve symptoms of enlarged prostate, such as frequent urination.
Cialis Lilly requires a prescription from a healthcare professional.
Possible side effects include headache, indigestion, back pain, and muscle aches.
It should not be combined with nitrates due to risk of severe hypotension.
Cialis Lilly does not protect against sexually transmitted infections.
The medication may interact with alpha-blockers, requiring caution.
It should be stored at room temperature away from moisture and heat.
Cialis Lilly is not recommended for use by women or children.

We are pleased to work with Sanofi to pursue a path that could allow more men who suffer from ED to obtain convenient access to a safe and reliable product without a prescription," said David Ricks, senior vice president, Lilly, and president, Lilly Bio-Medicines.

Product	Dosage	Quantity + Bonus	Price
Cialis Professional	20mg	30 Pills	104.57€ 99.59€
Cialis Generic	10mg	20 Pills	48.23€ 45.93€
Cialis Super Active	20mg	30 + 6 Pills	128.09€ 121.99€
Cialis Generic	40mg	60 + 6 Pills	130.98€ 124.74€
Cialis Original	20mg	48 + 4 Pills	224.69€ 213.99€
Cialis Super Active	20mg	20 + 4 Pills	92.35€ 87.95€
Cialis Black	80mg	10 Pills	43.27€ 41.21€
Cialis Professional	20mg	20 Pills	78.33€ 74.60€
Cialis Black	80mg	60 + 4 Pills	150.98€ 143.79€
Cialis Generic	40mg	90 + 6 Pills	171.35€ 163.19€
Cialis Original	20mg	76 + 4 Pills	319.19€ 303.99€
Cialis Generic	20mg	10 Pills	31.49€ 29.99€
Cialis Super Active	20mg	10 Pills	55.64€ 52.99€
Cialis Black	80mg	20 Pills	71.83€ 68.41€

"Switching a medicine to over-the-counter is a highly regulated process that is data-driven and scientifically rigorous.

It is one of the "big three" PDE5 inhibitors alongside Viagra and Levitra.
Its long duration is its primary competitive advantage.
Daily dosing offers a unique positioning versus on-demand competitors.
For BPH, it competes with alpha-blockers and 5-alpha reductase inhibitors.
In the post-patent market, generic tadalafil is the main competitor.
Brand strategy shifted to focus on specific patient segments.
Combination therapies for BPH/ED are an area of clinical interest.
Newer ED treatments (e.g., shockwave therapy) represent non-drug competition.

Cialis was first approved by the European Medicines Agency in 2002, then by the U.S. Food and Drug Administration in 2003, for the treatment of erectile dysfunction. Ultimately, Cialis has received approval in more than 120 countries for indications that vary by country, including erectile dysfunction and erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia (BPH). Cialis reached $2.16 billion USD (€1.58 billion) in worldwide sales in 2013 and has recorded total global sales of more than $14 billion USD (€10.2 billion) since launch. To generic cialis 10 pills date, more than 45 million men worldwide have been treated with Cialis. Currently only available with a prescription, Cialis is a tablet taken to treat erectile dysfunction (ED), the signs and symptoms of benign prostatic hyperplasia (BPH), and both ED and the signs and symptoms of BPH. Cialis is the only PDE-5 inhibitor treatment that offers men a choice when it comes to treatment for erectile dysfunction – Cialis for use as needed and Cialis for once daily use.

What Are the Key Risks and Uncertainties?

Sanofi Consumer Healthcare is committed to providing consumers around the world with self-care solutions that empower them to better manage their health and well-being through leading brands in the areas of Allergy, Digestive health, Feminine care, Cough, cold, flu & sinus and Vitamins, minerals & supplements. We place people at the very heart of everything we do and strive to identify and fulfil their needs by delivering consumer insights-driven innovation, leveraging our medical & scientific heritage and our close collaboration with healthcare professionals, easing consumer access via switching relevant prescription medicines to over-the-counter solutions and applying the pharmaceutical quality standards delivered by our Group's global manufacturing network. In 2013, Sanofi Consumer healthcare achieved a €3.0 billion ($4.1 billion USD) turnover representing a 5.2% growth vs. 2012 (constant exchange rates) and ranked #3 worldwide consumer healthcare player (Nicholas Hall- 2013). Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs.

How to flush Cialis out of your system?

Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. To learn more about Sanofi, please visit us at Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at and Cialis is available via prescription only and is approved to treat erectile dysfunction, or ED (2.5 mg, 5 mg, 10 mg, 20 mg), and both ED and the signs and symptoms of benign prostatic hyperplasia, or BPH (5 mg). ED is a medical condition in which a man has trouble getting or keeping an erection. It is very common: more than half of men over 40 years old have ED. Sanofi Consumer Healthcare is committed to providing consumers around the world with self-care solutions that empower them to better manage their health and well-being through leading brands in the areas of Allergy, Digestive health, Feminine care, Cough, cold, flu & sinus and Vitamins, minerals & supplements. We place people at the very heart of everything we do and strive to identify and fulfil their needs by delivering consumer insights-driven innovation, leveraging our medical & scientific heritage and our close collaboration with healthcare professionals, easing consumer access via switching relevant prescription medicines to over-the-counter solutions and applying the pharmaceutical quality standards delivered by our Group's global manufacturing network. In 2013, Sanofi Consumer healthcare achieved a €3.0 billion ($4.1 billion USD) turnover representing a 5.2% growth vs.

Cialis Lilly’s tadalafil works by inhibiting the PDE5 enzyme that restricts blood flow.
Its extended window allows sexual activity without strict timing constraints.
Clinical trials demonstrate significant improvements in erectile function.
Cialis Lilly is often preferred due to fewer visual side effects versus alternatives.
Combining alcohol with Cialis Lilly is not recommended as it may lower blood pressure.
The brand is commitment-driven to ongoing research and development.
Generic tadalafil products exist but Lilly’s brand emphasizes consistent dosing.
Cialis Lilly supports patient adherence through convenient packaging.
It is sometimes used off-label under medical guidance for pulmonary arterial hypertension.
Cost and insurance coverage vary depending on country and provider.

2012 (constant exchange rates) and ranked #3 worldwide consumer healthcare player (Nicholas Hall- 2013). Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.

Companies anticipate providing over-the-counter (OTC) product to treat erectile dysfunction after expiration of certain patents

Wishing Grünenthal great success in this new chapter! All the best, Nice to see this kind proyects in Latin America 👏 PARIS and INDIANAPOLIS, May 28, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Eli Lilly and Company (NYSE: LLY) today announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). Cialis is currently available by prescription only worldwide for the treatment of men with erectile dysfunction (ED). Under the terms of the agreement, Sanofi acquires the exclusive rights to apply for approval of Cialis OTC in the United States, Europe, Canada and Australia. Sanofi also holds exclusive rights to market Cialis OTC following Sanofi's receipt of all necessary regulatory approvals.

Highest Development Phases

If approved, Sanofi anticipates providing Cialis OTC after expiration of certain patents. Terms of the licensing agreement were not disclosed. "This agreement provides us with an opportunity to work with Lilly, a leader in men's health, to transform how this important medicine is offered to millions of men throughout the world," said Vincent Warnery, senior vice president, Global Consumer Healthcare Division, Sanofi. "The opportunity to forge an industry-leading partnership that adds to Sanofi Consumer Healthcare's leading portfolio and successful track record of over-the-counter switches reinforces consumer health care as a major growth platform for Sanofi." "Millions of men worldwide trust Cialis to treat ED. We are pleased to work with Sanofi to pursue a path that could allow more men who suffer from ED to obtain convenient access to a safe and reliable product without a prescription," said David Ricks, senior vice president, Lilly, and president, Lilly Bio-Medicines. To learn more about Sanofi, please visit us at Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at and Cialis is available via prescription only and is approved to treat erectile dysfunction, or ED (2.5 mg, 5 mg, 10 mg, 20 mg), and both ED and the signs and symptoms of benign prostatic hyperplasia, or BPH (5 mg). Taking Cialis with finasteride when starting BPH cialis cheapest treatment has been studied for 26 weeks. Important Safety Information for CIALIS® (tadalafil) tablets What Is The Most Important Information I Should Know About CIALIS?Do not take CIALIS if you: take medicines called "nitrates" such as isosorbide dinitrate or isosorbide mononitrate which are often prescribed for chest pain as the combination may cause an unsafe drop in blood pressure use recreational drugs called "poppers" like amyl nitrite and butyl nitrite are allergic to CIALIS or ADCIRCA® (tadalafil), or any of its ingredients.

Mechanism of action

"Switching a medicine to over-the-counter is a highly regulated process that is data-driven and scientifically rigorous. Cialis was first approved by the European Medicines Agency in 2002, then by the U.S. Food and Drug Administration in 2003, for the treatment of erectile dysfunction. Ultimately, Cialis has received approval in more than 120 countries for indications that vary by country, including erectile dysfunction and erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia (BPH). Cialis reached $2.16 billion USD (€1.58 billion) in worldwide sales in 2013 and has recorded total global sales of more than $14 billion USD (€10.2 billion) since launch.

Regulatory Approvals

To generic cialis 10 pills date, more than 45 million men worldwide have been treated with Cialis. Currently only available with a prescription, Cialis is a tablet taken to treat erectile dysfunction (ED), the signs and symptoms of benign prostatic hyperplasia (BPH), and both ED and the signs and symptoms of BPH. Cialis is the only PDE-5 inhibitor treatment that offers men a choice when it comes to treatment for erectile dysfunction – Cialis for use as needed and Cialis for once daily use. ED is a medical condition in which a man has trouble getting or keeping an erection. It is very common: more than half of men over 40 years old have ED. What Should I Tell My Healthcare Provider Before Taking CIALIS?CIALIS is not right for everyone. Before taking CIALIS, tell your healthcare provider about all your medical problems, particularly if you have or ever had: heart problems such as chest pain (angina), heart failure, irregular heartbeats, or have had a heart attack high or low blood pressure or have high blood pressure that is not controlled liver or kidney problems or require dialysis retinitis pigmentosa, a rare genetic (runs in families) eye disease severe vision loss, including a condition called NAION a deformed penis shape or Peyronie's disease an erection that lasted more than 4 hours blood cell problems such as sickle cell anemia, multiple myeloma, or leukemia Can Other Medicines Affect CIALIS?Tell your healthcare provider about all the medicines you take especially if you take: medicines called "nitrates" which are often prescribed for chest pain alpha-blockers often prescribed for prostate problems medicines for HIV or some types of oral antifungal medications some types of antibiotics such as clarithromycin, telithromycin, erythromycin (several brand names exist, please contact your healthcare provider to determine if you are taking this medicine) other medicines or treatments for erectile dysfunction (ED) CIALIS is also marketed as ADCIRCA for the treatment of pulmonary arterial hypertension. What Are The Possible Side Effects Of CIALIS?The most common side effects with CIALIS are: headache, indigestion, back pain, muscle aches, flushing, and stuffy or runny nose.

Topic	Key Points	Resources
Proper Dosage	Take as prescribed; do not exceed 20 mg per dose	Physician consultation
Timing with Food	Can be taken with or without food; delays absorption if high-fat meal	Patient leaflet
Alcohol Interaction	Avoid excessive alcohol as it may impair effectiveness	Medical advice
Recognizing Side Effects	Seek medical help if experiencing prolonged erections (>4 hours)	CDC guidelines

Psychological benefits include reduced anxiety about performance.
Can improve sexual satisfaction and overall quality of life for couples.
For BPH, benefits include reduced nocturia and improved urinary control.
Successful treatment may improve self-esteem and relationship dynamics.
Unrealistic expectations (e.g., automatic erection) can lead to disappointment.
Open communication with one's partner is encouraged.
Therapy or counseling may be needed alongside medication in some cases.
It is a treatment, not a cure, for the underlying conditions.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts.

More about Cialis (tadalafil)

Key Takeaways: Cialis vs Tadalafil

Taking Cialis with finasteride when starting BPH cialis cheapest treatment has been studied for 26 weeks. Important Safety Information for CIALIS® (tadalafil) tablets What Is The Most Important Information I Should Know About CIALIS?Do not take CIALIS if you: take medicines called "nitrates" such as isosorbide dinitrate or isosorbide mononitrate which are often prescribed for chest pain as the combination may cause an unsafe drop in blood pressure use recreational drugs called "poppers" like amyl nitrite and butyl nitrite are allergic to CIALIS or ADCIRCA® (tadalafil), or any of its ingredients. What Should I Tell My Healthcare Provider Before Taking CIALIS?CIALIS is not right for everyone. Before taking CIALIS, tell your healthcare provider about all your medical problems, particularly if you have or ever had: heart problems such as chest pain (angina), heart failure, irregular heartbeats, or have had a heart attack high or low blood pressure or have high blood pressure that is not controlled liver or kidney problems or require dialysis retinitis pigmentosa, a rare genetic (runs in families) eye disease severe vision loss, including a condition called NAION a deformed penis shape or Peyronie's disease an erection that lasted more than 4 hours blood cell problems such as sickle cell anemia, multiple myeloma, or leukemia Can Other Medicines Affect CIALIS?Tell your healthcare provider about all the medicines you take especially if you take: medicines called "nitrates" which are often prescribed for chest pain alpha-blockers often prescribed for prostate problems medicines for HIV or some types of oral antifungal medications some types of antibiotics such as clarithromycin, telithromycin, erythromycin (several brand names exist, please contact your healthcare provider to determine if you are taking this medicine) other medicines or treatments for erectile dysfunction (ED) CIALIS is also marketed as ADCIRCA for the treatment of pulmonary arterial hypertension. What Are The Possible Side Effects Of CIALIS?The most common side effects with CIALIS are: headache, indigestion, back pain, muscle aches, flushing, and stuffy or runny nose.

Market Size and Growth Rate

Uncommon but serious side effects include:An erection that won't go away: If you get an erection lasting more than 4 hours, seek immediate medical help to avoid long-term injury. protect a man or his partner from sexually transmitted diseases, including HIV serve as a male form of birth control For additional information, talk to your healthcare provider and please see the Full Prescribing Information, and Medication Guide. You may also learn more about Cialis at * The brand listed is a trademark of its respective owner and is not a trademark of Eli Lilly and Company. This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Although Sanofi's and Lilly's management believe that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of the companies, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. In particular, there are no guarantees that regulatory authorities will approve Cialis for nonprescription use. Risks and uncertainties also include, among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Companies' ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2013, and in the public filings with the SEC made by Lilly, including those listed under "risk Factors" in Lilly's annual report on Form 10-K for the year ended December 31, 2013.